KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Accumulated Expenses: 2010-2025

Historic Accumulated Expenses for Nektar Therapeutics (NKTR) over the last 15 years, with Sep 2025 value amounting to $28.6 million.

  • Nektar Therapeutics' Accumulated Expenses fell 11.68% to $28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.6 million, marking a year-over-year decrease of 11.68%. This contributed to the annual value of $30.0 million for FY2024, which is 35.24% up from last year.
  • Per Nektar Therapeutics' latest filing, its Accumulated Expenses stood at $28.6 million for Q3 2025, which was down 18.53% from $35.1 million recorded in Q2 2025.
  • Nektar Therapeutics' 5-year Accumulated Expenses high stood at $37.4 million for Q1 2023, and its period low was $15.7 million during Q4 2021.
  • For the 3-year period, Nektar Therapeutics' Accumulated Expenses averaged around $30.0 million, with its median value being $29.7 million (2023).
  • Per our database at Business Quant, Nektar Therapeutics' Accumulated Expenses spiked by 132.33% in 2022 and then crashed by 39.38% in 2023.
  • Quarterly analysis of 5 years shows Nektar Therapeutics' Accumulated Expenses stood at $15.7 million in 2021, then surged by 132.33% to $36.6 million in 2022, then crashed by 39.38% to $22.2 million in 2023, then surged by 35.24% to $30.0 million in 2024, then fell by 11.68% to $28.6 million in 2025.
  • Its last three reported values are $28.6 million in Q3 2025, $35.1 million for Q2 2025, and $31.3 million during Q1 2025.